PTP4A3 (PRL3-zumab Biosimilar) Recombinant Monoclonal Antibody

1. PRL-3 may be a reliable biomarker for early prostate cancer detection and may provide a predictive indicator of tumor progression PMID: 29207031
2. The proliferation and invasion of colorectal cancer cells were enhanced significantly by PRL-3 through improving glycolysis. PMID: 28791350
3. We conclude that PRL-3 is an important regulatory factor for breast cancer cell proliferation and invasion. Loss of PRL-3 function induces an antimetastatic gene expression profile in breast cancer cells. Due to its role in tumor growth and metastasis, PRL-3 emerges as a new therapeutic target in breast cancer therapy. PMID: 28980126
4. Since high PRL-3 expression also correlates with poor prognosis in other cancers and functional studies in PC support these findings, PRL-3 emerges as a potential treatment target in PC PMID: 29190795
5. Data show that phosphatase of regenerating liver-3 (PRL-3a) is an important mediator of growth factor signaling in MM cells and hence possibly a good target for treatment of MM. PMID: 27036022
6. Data suggest that phosphatase of regenerating liver-3 (PRL-3)might play a tumor suppressor role in lung cancer, distinct from other cancers, by inhibiting epithelial-mesenchymal transition (EMT)-related pathways. PMID: 26967563
7. A novel role of PRL-3 in tumor development through its adverse impact on telomere homeostasis. PMID: 28482095
8. our result indicated that PRL-3 promotes protein phosphorylation by acting as an 'activator kinase' and consequently regulates cytokine secretion. PMID: 28068414
9. The disruption of epithelial architecture by PRL-3 revealed here is a newly recognized mechanism for PRL-3-promoted cancer progression. PMID: 27656108
10. This study suggests PRL-3 and SFKs are key mediators of the IL6-driven signaling events. PMID: 27698077
11. Regulation of PTP4A3 expression is altered in specific subgroups of acute leukemias and this is likely brought about by expression of the aberrant ETV6-RUNX1 and BCR-ABL1 fusion genes. PMID: 28063378
12. PRL-3 engages the focal adhesion pathway in trip0le-negative breast cancer cells as a key mechanism for promoting TNBC cell migration and invasion. PMID: 27452906
13. PTP4A3 regulated glioblastoma multiforme via miR-137-mediated Akt/mTOR signaling pathway. PMID: 27328425
14. Studies suggest that transcriptional, translational, or posttranslational regulation might be involved in the aberrant expression of phosphatase of regenerating liver (PRL)-3. PMID: 27911713
15. we observed that PRL-3 regulated the clustering of integrin beta1 in FAs on collagen I but not on fibronectin. This work identifies PRL-3 as a new regulator of cell adhesion structures to the extracellular matrix, and further supports PRL-3 as a key actor of metastasis in uveal melanoma, of which molecular mechanisms are still poorly understood PMID: 28284838
16. PTP4A3 may play a role in bladder cancer oncogenesis and is a predictive marker of metastasis. PTP4A3 overexpression represents an independent prognosticator for BC, suggesting its potential theranostic value. PMID: 26433386
17. our results provide a bridge between PRL-3 and PTEN; PRL-3 decreased the expression of PTEN as well as increased the level of PTEN phosphorylation and inactivated it, consequently activating the PI3K/Akt signaling pathway, and upregulating MMP-2/MMP-9 expression to promote gastric cancer cell peritoneal metastasis. PMID: 27572739
18. PRL-3 promotes cell migration and invasion via the NF-kappaB-HIF-1alpha-miR-210 axis. High levels of PRL-3 and miR-210 are related with poor OS in gastric cancer. PMID: 26548949
19. Data suggest that induction of PRL3 (phosphatase of regenerating liver-3) contributes to increased cytoskeleton reorganization, increased cell motility, and possibly increased invasiveness of endometrial stromal cells (ESC) from subjects with endometrioma as compared to ESC from normal subjects. PMID: 26874360
20. Results uncovered that aberrant overexpression of PRL-3 could initiate chordoma in early development. PMID: 26846972
21. Role of PRL-3 in the development, migration, and invasion of salivary adenoid cystic carcinoma (SACC). PMID: 26041460
22. PRL-3 has a role in the pathogenesis of prostate cancer. PMID: 26975394
23. PRL-3 provides a strategic survival advantage to tumour cells via its effects on mTOR. PMID: 26597054
24. Promotes uveal melanoma aggressiveness via membrane accumulation of matrix metalloproteinase 14 (MMP14) PMID: 27096756
25. Our findings suggested that PRL-3 genomic gain may represent an aggressive phenotype of primary colorectal cancer PMID: 26563151
26. Examination of clinical samples confirmed that USP4 expression positively correlates with PRL-3 protein expression, but not mRNA transcript levels. PMID: 26669864
27. PTP4A3 over expression independently predicted the metastasis and outcome of upper tract urothelial carcinoma, which was even more important in organ confined disease. PMID: 26070892
28. Data inticate that heat shock protein 60 (HSP60) interacted constitutively with NKG2D ligand ULBP2 and phosphatase of regenerating liver 3 (PRL-3) regulated HSP60 tyrosine phosphorylation. PMID: 25687758
29. These studies reveal a critical role of autophagy in PTP4A3-driven cancer progression. PMID: 25136802
30. miR-495 methylation-associated silencing inhibits the migration and invasion of human gastric cancer cells by directly targeting PRL-3 PMID: 25475733
31. Tumor-associated macrophages participate in the metastasis of CRC induced by PRL-3 through secretion of IL-6 and IL-8 in a KCNN4 dependent manner. PMID: 24885636
32. STAT3 binds to the -201 to -210 region of PRL-3. STAT3 functionally regulates PRL-3. STAT3 core signature was enriched in AML with high PRL-3 expression. The STAT3/PRL-3 regulatory loop contributes to the pathogenesis of AML. PMID: 25139404
33. The expression of PRL-3, but not of E-cadherin, was associated with shorter survival of patients. PRL-3 and E-cadherin exhibit interactions in gastric cancer and are involved in the formation of lymph node metastases PMID: 24696260
34. Aberrant PRL-3 expression promoted cell cycle progression and enhanced the antiapoptotic machinery of AML cells to drug cytotoxicity through downregulation of p21 and upregulation of Cyclin D1 and CDK2 and activation of STAT5 and AKT. PMID: 24737397
35. PRL-3 and Leo1 levels were positively associated in AML patient samples. PMID: 24686170
36. Studies indicate a significant association of phosphatase of regenerating liver 3 (PRL-3) overexpression with overall survival and some clinicopathological features in gastric cancer. PMID: 24204707
37. PRL3 provokes a tyrosine phosphoproteome to drive prometastatic signal transduction. PMID: 24030100
38. The strong expression of PRL-3 in the primary tumor that was significantly correlated with the grade and clinical stage suggest that PTP4A3 participates in the process of endometrial carcinogenesis. PMID: 23729584
39. PRL-3 induces microvascular vessel formation by facilitating VEGF expression in endometrial adenocarcinoma tissues PMID: 23989302
40. These findings strongly support a role for PTP4A3 as an important contributor to endothelial cell function and as a multimodal target for cancer therapy and mitigating VEGF-regulated angiogenesis. PMID: 24403062
41. Clinically, high PRL-3 mRNA expression was associated with FLT3-ITD mutations in four independent acute myeloid leukaemia datasets with 1158 patients. PMID: 23929599
42. PRL-3 is phosphorylated downstream of Src, and this phosphorylation is required for PRL-3 to promote invasion, motility and activation of RhoC in cell culture systems. PMID: 23691193
43. our findings demonstrate that PRL-3-targeted DNA vaccine can generate significantly preventive and therapeutic effects on the growth of breast cancer expressing PRL-3 through the induction of cellular immune responses to PRL-3 PMID: 23364316
44. PRL-3-induced hyperactivation of EGFR correlates with increased cell growth, promigratory characteristics, and tumorigenicity in colorectal cancer. PMID: 23867504
45. Explored the mechanism by which PRL-3 mediates EMT. Demonstrated that PRL-3 induced the expression of KCNN4 channels, leading to EMT and the down-regulation of E-cadherin. PMID: 23572150
46. The ability of DHEA to target prenylation pathway could be utilized to inhibit PRL-3 prenylation for successful prevention of CRC metastases. PMID: 23462371
47. PRL-3 plays a critical role in ovarian cancer tumorigenicity and maintaining the malignant phenotype. PRL-3 may inhibit c-fos transcriptional regulation of integrin alpha2 signaling. PMID: 23418787
48. PRL-3 expression was related to LVI or necrosis which is important for tumor invasiveness, we could not find that PRL-3 as an important prognostic factor in breast cancer patient PMID: 22855168
49. High expression of the PRL-3 gene might be a useful predictor of poor postoperative outcome in patients with colorectal cancer. PMID: 22440248
50. PRL-3 is a key regulator of histone demethylation. JMJD1B seems to be a candidate tumour suppressor and JMJD2B seems to be a potential oncoprotein in the development and progression of CRC. PMID: 22345654

Show More

Hide All

HGNC: 9636

OMIM: 606449

KEGG: hsa:11156

STRING: 9606.ENSP00000332274

UniGene: Hs.43666